Article

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

2024-05-06

Abstract excerpt

Despite the potential of targeted epigenetic therapies, most cancers do not respond to current epigenetic drugs. The Polycomb repressive complex EZH2 inhibitor tazemetostat was recently approved for the treatment of SMARCB1 -deficient epithelioid sarcomas, based on the functional antagonism between PRC2 and loss of SMARCB1. Through the analysis of tazemetostat-treated patient tumors, we recently defined key princ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 39dc8c72-5d1c-58aa-965c-6922399a1abd
DOI: 10.1101/2024.05.03.592420

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasDOI 10.1101/2024.05.03.592420Read

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.Semantic proximity Read

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read

PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral MimicrySemantic proximity Read

The epigenomics of sarcoma.Semantic proximity Read

ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survivalSemantic proximity Read

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancersSemantic proximity Read

Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer.Semantic proximity Read

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.Semantic proximity Read

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancerSemantic proximity Read